Myeloablative therapy prior to bone marrow transplant (BMT) can cause irreversible primordial follicle damage and premature ovarian insufficiency (POI). One option for fertility preservation in young patients is ovarian tissue cryopreservation (OTC). There is limited literature on the possible impact on ovarian reserve, death, and complications following OTC. We hypothesize that patients undergoing OTC and BMT will have no difference in complications compared to those who have undergone BMT alone.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Pediatric and Adolescent Gynecology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect